HSPB1 and Familial prostate cancer: To further test the ability of digitoxin to suppress EMT, we used RNA-seq to examine the effect of digitoxin on the expression and ratio of mRNAs for HSPB1 and RBFOX2. HSPB1 is a positive biomarker for EMT in prostate cancer (35), while RBFOX2, regulates both epithelial and mesenchymal splicing events (36).